Hematogenix's Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
RegulatoryapprovedZENBEXUSPositive
AI Analysis
Summary
Bristol Myers Squibb received FDA accelerated approval for ZENBEXUS (iberdomide), the first approved CELMoD therapy for multiple myeloma, with efficacy evaluated using Hematogenix's proprietary MM MRD assay as the primary endpoint.
Outcome Details
FDA Accelerated Approval of ZENBEXUS (iberdomide), the first approved CELMoD therapy for multiple myeloma
Importance:8/10
Sentiment:
0.85
FDA ApprovalAccelerated ApprovalMultiple MyelomaCELMoDMRD AssayDiagnosticsOncology
Related Companies
Read the original article
Published by PR Newswire Biotech on August 14, 2026 10:20 PM